Involvement of Circulating Aminoterminal Propeptide of Type 3 Procollagen in Cardiovascular Events in Patients on Hemodialysis
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 244
- Locations
- 1
- Primary Endpoint
- Cardiovascular events
Study Overview
Brief Summary
This study evaluates whether circulating levels of aminoterminal propeptide of type III procollagen (PIIINP) can predict the cardiovascular events in hemodialysis patients.
Detailed Description
Type III collagen abundantly exists in the cardiovascular system including the aorta and heart. The aminoterminal propeptide of type III procollagen (PIIINP) is an extension peptide of type III procollagen, which is cleaved off stoichiometrically during conversion from type III procollagen to type III collagen and liberated to serum. Elevated serum concentrations of PIIINP are considered a marker of higher collagen turnover and tissue fibrosis including the heart and vascular system. In this study, the investigators prospectively examined whether serum levels of PIIINP could be a biomarker for predicting cardiovascular events in hemodialysis patients.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •End-stage kidney disease patients who had been undergoing maintenance hemodialysis over one year in Toujinkai Hospital at the point of January 1, 2005
Exclusion Criteria
- •Histories of coronary events and/or interventions
- •Congestive heart failure of New York Heart Association grades III to IV
- •Moderate or worse valvular heart disease
- •Permanent pacemaker implantation
- •Idiopathic cardiomyopathy
- •Chronic obstructive pulmonary disease
- •Malignancy
- •Acute hepatitis, chronic hepatitis, or liver cirrhosis including carrier of hepatitis virus
Outcomes
Primary Outcomes
Cardiovascular events
Time Frame: January 1, 2005 to January 31, 2011
Cardiac deaths, non-fatal acute myocardial infarction, obstructive coronary artery disease needing intervention, vasospastic angina identified by angiography, heart failure needing hospitalization, bradycardia needing pacemaker implantation, dissecting aortic aneurysm, cardiac valvular disease needing valve replacement, peripheral artery disease needing bypass surgery or leg amputation.
Secondary Outcomes
No secondary outcomes reported
Investigators
Masato Nishimura, MD
Director of Cardiovascular division
Toujinkai Hospital